Last updated: June 19, 2026
Litigation Summary and Analysis for Purdue Pharmaceuticals Products L.P. v. Lannett Holdings, Inc. (2:15-cv-06036)
Executive summary
- Case: Purdue Pharmaceuticals Products L.P. v. Lannett Holdings, Inc., 2:15-cv-06036
- Parties: Purdue Pharmaceuticals Products L.P. (plaintiff) vs. Lannett Holdings, Inc. (defendant).
- Procedural posture and merits: Not provided in the input. A litigation summary that is accurate requires docket outcomes (complaint claims, asserted patents, court rulings, dates, and settlement/consent judgments). Those facts are not included here, so a complete, reliable analysis cannot be produced from the provided information.
What is the lawsuit about in Purdue v. Lannett (2:15-cv-06036)?
A litigation summary requires: (i) the patent(s) asserted, (ii) whether Purdue brought Hatch-Waxman (35 U.S.C. § 271(e)(2)) claims via an ANDA, and (iii) the relief requested (injunction, declaratory judgment, damages, or dismissal). None of those case-critical details are included in the prompt, so the underlying claims cannot be characterized.
What type of IP claim is typically at issue in this fact pattern?
Cases brought by Purdue in opioid-related generic disputes usually involve one of the following:
- Paragraph IV patent infringement tied to an ANDA for a Purdue product, with timing tied to FDA approvals and marketing dates.
- Section 271(e)(2) theory based on the filing of an ANDA with a paragraph IV certification.
No assertion-specific information is provided for this docket, so the claim type cannot be confirmed for 2:15-cv-06036.
Which patents did Purdue assert against Lannett in 2:15-cv-06036?
A correct “which patents” section depends on:
- the list of asserted U.S. patents
- the publication/application numbers if relevant
- which counts correspond to each patent
- whether Purdue asserted composition, formulation, method-of-use, or manufacturing claims
The prompt provides only the case caption and docket number, not the asserted patent list. A patent-by-patent analysis therefore cannot be produced.
What did the court decide in Purdue v. Lannett (2:15-cv-06036)?
To summarize and analyze the decision, a docket outcome is required:
- claim construction rulings
- infringement and validity rulings
- summary judgment outcomes
- trial verdicts (if any)
- post-judgment motions (Rule 50/59, appeal status)
The prompt provides no rulings, dates, or disposition. A decision summary would be speculative and is not permissible.
How did Purdue’s licensing and settlement position affect the litigation?
Many Purdue generic disputes resolve via:
- a settlement agreement with agreed launch dates or non-infringement positions
- covenant not to sue
- payment terms (where permitted) and dismissal terms
No settlement terms or even whether a settlement occurred are included in the prompt. Without the docket’s disposition or settlement documents, this cannot be analyzed.
What is the Paragraph IV and FDA ANDA timeline impact for 2:15-cv-06036?
A timeline analysis requires:
- which FDA product (drug strength, dosage form, and label)
- which ANDA number(s)
- filing date of the ANDA
- the paragraph IV certification date
- the 30-month stay start/end (if applicable)
- any court orders affecting exclusivity or market entry
Those elements are not provided.
When do Purdue-related exclusivity events typically matter?
Where opioid product disputes are litigated under Hatch-Waxman, exclusivity and court-ordered stays often determine:
- whether a generic can launch before judgment
- whether a court’s finding triggers earlier or delayed approval/marketing
But the input does not identify the FDA pathway or product at issue for 2:15-cv-06036.
What did Lannett’s invalidity and non-infringement arguments rely on?
A proper invalidity analysis needs the specific defenses raised:
- anticipation or obviousness theories, including whether prior art is chemical, regulatory, or publication-based
- inequitable conduct allegations (if any)
- non-infringement claim scope arguments tied to formulation, dosage delivery, or method steps
The prompt does not include the defense positions or court treatment, so a defense analysis cannot be prepared.
How strong was Purdue’s patent estate in this case?
“Strength” requires:
- the number and type of asserted patents
- which patents survived dispositive motions
- whether claim construction favored Purdue
- whether infringement findings were likely based on the generic’s ANDA disclosures
No patent estate details are provided for the specific docket.
What are the generic launch risks if Lannett prevailed or settled?
Risk analysis needs:
- the ultimate case outcome (dismissal, injunction, settlement terms)
- the agreed launch date (if any)
- whether there are carve-outs by strength, dosage form, or market geography
- whether other defendants or co-pending litigations exist
None of those facts are provided.
Does this case affect other Purdue generic challenges?
Impact analysis requires cross-references:
- whether the same asserted patents were litigated in related cases
- whether the case generated precedential claim construction
- whether collateral estoppel or law-of-the-case factors matter
The prompt does not include any related-case mapping.
Key Takeaways
- No litigation outcome, asserted patents, or FDA/ANDA timeline details are provided for Purdue Pharmaceuticals Products L.P. v. Lannett Holdings, Inc., 2:15-cv-06036.
- A litigation summary and analysis that is accurate requires docket-specific facts that are not included in the input.
FAQs
- What patents were asserted in Purdue v. Lannett (2:15-cv-06036)?
- Was 2:15-cv-06036 resolved by judgment or settlement?
- What was the impact of any 30-month stay in 2:15-cv-06036?
- Did the court issue claim construction for Purdue’s asserted claims in 2:15-cv-06036?
- What generic product and dosage form did Lannett seek to market in relation to 2:15-cv-06036?
References (APA)
- Purdue Pharmaceuticals Products L.P. v. Lannett Holdings, Inc., No. 2:15-cv-06036 (filed 2015).
